Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar-Apr;62(2):195-199.
doi: 10.4103/ijd.IJD_233_16.

Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis

Kiran Godse  1
Affiliations

Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis

Kiran Godse. Indian J Dermatol. 2017 Mar-Apr.

Abstract

Psoriasis is a complex inflammatory disease that occurs in genetically susceptible individuals and presents with the development of erythematous scaly plaques on the skin. Interleukins (ILs) in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. Secukinumab is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. Secukinumab recently approved for use as first-line systemic therapy in a patient with moderate to severe psoriasis has been studied first in psoriasis before other diseases. Both Phase II and III clinical trials have demonstrated the effectiveness of secukinumab in the treatment of moderate-to-severe plaque psoriasis, and it has demonstrated superiority to other comparable biologics on the market, including the tumor necrosis factor inhibitor etanercept. Secukinumab has also shown superiority to ustekinumab, a relatively recent biologic introduced for the treatment of psoriasis. Besides demonstrating better efficacy compared to etanercept and ustekinumab, secukinumab has also demonstrated a greater impact of the quality of life of patients with a comparable safety profile. Secukinumab shows great promise in having a tremendous impact on the treatment of plaque psoriasis based on its ability to produce similar, if not better, clinical outcomes than other biologic antipsoriasis medications.

Keywords: Biologics; Interleukin-17; PASI; monoclonal antibody; psoriasis; secukinumab.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest. What is new? Secukinumab is the first biological drug approved for the first-line treatment of patients with psoriasis eligible for systemic therapySecukinumab sets a new benchmark for clinical efficacy with a PASI 90 response rate of around 80% by week 16.

Figures

Figure 1
Figure 1
Psoriasis Area and Severity Index 75 at week 12 across three Phase III studiesa with secukinumab 300 mg in patients with moderate-to-severe psoriasis. *P < 0.001, **P < 0.0001, aComparator: Placebo in ERASURE, Etanercept in FIXTURE and ustekinumab in CLEAR. ERASURE: Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis; FIXTURE: Full Year Investigative Examination of Secukinumab versus Etanercept using Two Dosing Regimens to Determine Efficacy in Psoriasis, CLEAR: Comparison to assess Long-term Efficacy, sAfety and toleRability of secukinumab vs. ustekinumab
Figure 2
Figure 2
Psoriasis Area and Severity Index 90 at week 12 across three Phase III studiesa with secukinumab 300 mg in patients with moderate-to-severe psoriasis. *P < 0.001, **P < 0.0001, aComparator: Placebo in ERASURE, Etanercept in FIXTURE and ustekinumab in CLEAR. ERASURE: Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis; FIXTURE: Full Year Investigative Examination of Secukinumab versus Etanercept using Two Dosing Regimens to Determine Efficacy in Psoriasis, CLEAR: Comparison to assess Long-term Efficacy, sAfety and toleRability of secukinumab vs. ustekinumab
Figure 3
Figure 3
Psoriasis Area and Severity Index 100 at week 12 across three Phase III studiesa with secukinumab 300 mg in patients with moderate-to-severe psoriasis. *P < 0.001, **P = 0.0003, aComparator in Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis was placebo, in Full Year Investigative Examination of Secukinumab versus Etanercept using Two Dosing Regimens to Determine Efficacy in Psoriasis was etanercept and in Cancer Lifestyle and Evaluation of Risk was ustekinumab
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sarkar S, Sarkar A, Saha R, Sarkar T. Psoriasis and psychiatric morbidity: A profile from a tertiary care centre of Eastern India. J Family Med Prim Care. 2014;3:29–32. - PMC - PubMed
    1. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010;76:595–601. - PubMed
    1. Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis – Best use of biologics. Expert Rev Clin Immunol. 2014;10:269–79. - PubMed
    1. Gisondi P, Dalle Vedove C, Girolomoni G. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol Ther (Heidelb) 2014;4:1–9. - PMC - PubMed
    1. Roman M, Madkan VK, Chiu MW. Profile of secukinumab in the treatment of psoriasis: Current perspectives. Ther Clin Risk Manag. 2015;11:1767–77. - PMC - PubMed
-